ACD-2019
Undisclosed CNS Target
Discovery/PreclinicalActive
Key Facts
About Acadia Pharmaceuticals
Acadia Pharmaceuticals' mission is to advance care for underserved neurological and rare disease communities by developing and commercializing innovative treatments where few or no options exist. Its key achievements include the landmark approvals of NUPLAZID® for Parkinson's disease psychosis and DAYBUE® for Rett syndrome, establishing two commercial pillars. The company's strategy is to leverage its commercial infrastructure and CNS expertise to maximize these assets while advancing a pipeline targeting significant adjacent indications like Alzheimer's disease psychosis. Acadia operates as a fully integrated, publicly traded organization with a growing international footprint.
View full company profileTherapeutic Areas
Other Undisclosed CNS Target Drugs
| Drug | Company | Phase |
|---|---|---|
| OliX Collaboration (siRNA) | Key2Brain | Research |
| MGX Platform (Nuclease) | Metagenomi | Preclinical |